Healthpeak Properties Inc (DOC)

Rating: HOLD

HOLD (5-tier) · income compounder · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -6% vs spot
• Monte Carlo median implies -14% vs spot
• Bear case (Structural — Rate Shock / Oversupply / Secular Decline) downside is -52% vs spot
• Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $21.40 (Alpha Vantage, 2026-06-27) Healthpeak trades at 11.5x guided FFO of $1.88 with a 5.75% dividend yield, within 1% of its 52-week high of $21.55. The market is pricing a stable-rate, slow-growth outpatient and lab landlord: mid-single-digit same-store NOI growth, no re-rating, income as the return. The engine differs on the left tail, not the base. Variance decomposition attributes 83% of outcome dispersion to the multiple, and the scenario set carries a 20% structural state of rate shock plus lab oversupply with a $10.51 target below the 52-week low of $15.18, alongside a 17% recession state at $17.01. Probability-weighting all five paths gives $20.68, 3% below spot, hence HOLD: the base case at $21.75 is already priced, and peer forward P/E medians near 33.8x are not a usable anchor for a levered REIT carrying $9.54B of net debt. The single most damaging risk is a sustained cap-rate reset in which FFO and the multiple compress together.

The dashboard below is the whole argument on one page: spot ($22) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case carries 20% weight and is mechanically simple. Life-science supply additions keep lab vacancy elevated for years, so renewal spreads turn negative just as higher-for-longer rates push cap rates out. Same-store NOI declines, occupancy slips, and FFO per share erodes towards $1.50 while the applied multiple compresses to roughly 8x; both legs of the valuation fail at once. With $9.54B of net debt, refinancing at higher coupons absorbs a growing share of NOI, and the $0.85B annual dividend leaves little retained cash to deleverage, so a dividend reset becomes plausible rather than remote. The implied $10.51 target sits below the 52-week low, which means the market has not yet priced this path, and nothing in current prints refutes it.

Key Debate

P/E Multiple explains 83% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.44 vs analyst floor +0.00 → delta +0.44 (n=25 mgmt / 16 Q&A; 60th pctile across the S&P book, z +0.3).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 180 articles): avg ticker sentiment +0.15 (bullish 8% / bearish 1%)

Scenario Analysis

The tree runs from a structural 'Structural — Rate Shock / Oversupply / Secular Decline' downside ($10) to a 'Bull — Cap-Rate Compression / Re-Rate' bull case ($32); the probability-weighted blend (PWEV $21) is -6% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Rate Shock / Oversupply / Secular Decline (20%, $10). Structural impairment — rate shock / oversupply / secular decline: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 10.51; probability: 0.2.
• Recession / Occupancy & SS-NOI Decline (17%, $17). Cyclical downturn — same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend weakens for 1–2 years before normalising. Drivers — implied_target: 17.01; probability: 0.17.
• Base — FFO Growth + Stable Cap Rates (35%, $22). Mid-cycle — normalised same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend; disciplined capital allocation; steady returns. Drivers — implied_target: 21.75; probability: 0.35.
• Growth — Same-Store NOI + External Growth (20%, $28). Upside — NOI growth + cap-rate compression lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 27.46; probability: 0.2.
• Bull — Cap-Rate Compression / Re-Rate (8%, $32). Upside tail — sustained tight conditions or a structural re-rate on NOI growth + cap-rate compression. Drivers — implied_target: 32.29; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

peer P/E re-rate excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

FFO, P/FFO & Distributions

For a REIT, GAAP EPS is meaningless — depreciation is a massive non-cash charge, so REITs are valued on Funds From Operations (FFO ≈ net income + real-estate D&A) and P/FFO, not P/E. Every 'earnings' and 'multiple' figure in this report is therefore on an FFO basis.

The valuation runs on FFO × P/FFO (the standard REIT frame); the cash-flow DCF is omitted (a REIT's development/maintenance capex is funded against the asset base, not free cash). The dividend yield (5.8%) is the income anchor; cap-rate / interest-rate moves and same-store NOI drive the scenarios.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $19 and 30% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (83% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 33.785x) implies $64. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 20% so the market's mood does not drive the fair value.

Across all anchors the spread is 152% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Real Estate

This name sits in the Real Estate as a reit_core. same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: WELL (reit_core) · PLD (reit_growth) · EQIX (reit_growth) · SPG (reit_core) · AMT (reit_growth) · DLR (reit_growth) · O (reit_core) · PSA (reit_core) · VTR (reit_core) · CBRE (real_estate_services) · IRM (reit_cyclical) · CCI (reit_growth) · EXR (reit_core) · VICI (reit_core) · AVB (reit_core) · EQR (reit_core) · SBAC (reit_growth) · ESS (reit_core) · WY (reit_cyclical) · INVH (reit_core) · HST (reit_cyclical) · MAA (reit_core) · REG (reit_core) · DOC (reit_core) · UDR (reit_core) · CSGP (real_estate_services) · BXP (reit_cyclical) · CPT (reit_core) · FRT (reit_core) · ARE (reit_cyclical)

Mapping note: name-level 'Structural — Rate Shock / Oversupply / Secular Decline' (20%) + 'Recession / Occupancy & SS-NOI Decline' (17%) map to cluster Rate Shock / Oversupply / Demand Loss (37%); name-level 'Growth — Same-Store NOI + External Growth' (20%) + 'Bull — Cap-Rate Compression / Re-Rate' (8%) map to cluster Upside — NOI Growth / Cap-Rate Compression (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Rate Shock / Oversupply / Demand Loss () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The real_estate cycle is the shared macro driver. Driver — same-store NOI + occupancy + FFO growth + cap rates / interest rates + property demand Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.5% of revenue; cash conversion (OCF/NI) 1240% — cash-backed.

Catalyst Calendar

• 2026-05-01 (~-68d) — Life-science lab leasing / occupancy and supply-absorption update (authored)
• 2026-08-04 (~27d) — Quarterly earnings — est. EPS $0.44 (AV EARNINGS_CALENDAR)
• 2026-09-30 (~84d) — Merger integration synergy and disposition-programme milestone (authored)
• 2027-02-10 (~217d) — FY2027 FFO and same-store NOI guidance (authored)

Forecast Track Record

• EPS surprise: beat 37.5% of the last 8 quarters; average surprise +12.8%.

Competitive Moat

Narrow moat. On-campus medical-office and purpose-built lab locations near health systems create sticky, high-retention tenancy, but this is a modest location moat not a franchise; falsifiable claim — if same-store NOI growth cannot sustain ~3% and lab oversupply pushes occupancy lower, the moat does not justify any premium and the FFO multiple should sit at the low-11x it already trades — a discount, not a premium.

Moat sources:

• On-campus / health-system-affiliated medical outpatient buildings with high tenant retention
• Purpose-built life-science lab assets in innovation clusters (specialised, hard to relocate)
• Long-lease credit tenancy tied to hospital systems
• Scale and cost of capital vs sub-scale healthcare landlords

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 118.0× forward EPS, and a peer median 33.785×.

Variant perception: the house view is below-consensus, and the thesis is primarily margin-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 31.7× (simple median 33.785×). Direct peers count 100%, segment 50%, broad 25%.

Valuation-anchor screen: Peer (fwd P/E) (valid but extreme (>100% over median)). Anchor median 20.7. Extreme/excluded anchors carry no headline weight.

Historical-range cross-check: 52-week range $15–$22, centre $18 (-18% vs spot); spot sits at the 106th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Cap-Rate Compression / Re-Rate): $32.

Assumption Register

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

No DCF anchor is meaningful for this asset; the blend leans 50% on probability-weighted scenarios and 30% on the Monte Carlo median — the scenario probabilities are the load-bearing inputs.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Same-store cash NOI growth (blended portfolio) < 1.5% (2 consecutive prints → real_estate). Midpoint between the base path (5% revenue growth on stable margins) and the recession path (negative growth). Two prints below 1.5% indicate the cycle has broken towards the $17.01 recession scenario.
• Lab segment occupancy < 93% (2 consecutive prints → real_estate). The structural scenario mechanism is life-science oversupply. Sustained lab occupancy below 93% means new-supply absorption has failed and negative renewal spreads follow, validating the impairment path towards $10.51.
• FY FFO-as-adjusted per share guidance < $1.80 (single event → real_estate). Guided FFO of $1.88 anchors the base valuation at 11.5x. A guidance reset below $1.80 removes the base-case earnings floor and shifts weight to the bear scenarios.
• Net debt / adjusted EBITDA > 6.0x (2 consecutive prints → real_estate). Net debt is $9.54B against $2.9B revenue. Leverage drifting above 6.0x in a higher-rate regime forces asset sales or equity issuance at depressed prices, the funding leg of the structural scenario.
• Common dividend declared per share < $0.305 quarterly (single event → real_estate). The $0.85B payout (AV FY2025) underpins the 5.75% yield that supports the multiple. Any cut signals the board sees cash coverage failing, and the income-buyer shareholder base exits.

Fact / Inference / Speculation

• FACT: Spot $22; 52-week range $15–$22; engine rating HOLD; base-case target $21 (-6%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $20 (-9% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $29 (+31% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.